Section 4 of Chapter 4 makes explicit what might otherwise be assumed: compliance with the Guidelines does not exhaust a company's obligations. Multiple regulatory regimes and self-regulatory standards apply simultaneously to pharmaceutical sales information activities, and companies must satisfy all of them at once.

The core message: The Guidelines are one layer in a stack of overlapping rules. A company that reads only the Guidelines and ignores the rest is not compliant — it has simply not yet been caught violating another rule.

01The Fair Competition Code

The Fair Competition Code for Prescription Drugs is an industry self-regulatory standard adopted under Japan's Act against Unjustifiable Premiums and Misleading Representations (the Premiums and Representations Act). It governs the provision of goods, entertainment, and other benefits to healthcare professionals — the dimension of sales activity that the Guidelines do not cover. The Guidelines regulate what information is provided and how; the Fair Competition Code regulates what else accompanies the information.

So what (what it means): A meeting that complies fully with the Guidelines may still violate the Fair Competition Code if a gift distributed there or a meal provided exceeds the permitted limits. The two frameworks are complementary, not redundant — and both must be satisfied.

So why (why it is written this way): The "quality" of information and the "value of accompanying benefits" are regulated separately because they serve distinct anti-corruption functions. Even accurate, compliant information becomes suspect if attached to financial inducements that could influence the prescriber's judgment.

02The Pharmaceutical and Medical Device Act and Other Legislation

Article 68 of the Pharmaceutical and Medical Device Act (PMDA Act) prohibits advertising unapproved indications, creating direct overlap with the Guidelines. But the PMDA Act is a comprehensive framework covering manufacturing, quality, distribution, and pharmacovigilance — not just advertising. Sales information activities must be consistent with all applicable provisions, not only those that most visibly intersect with promotion.

So what (what it means): The Guidelines sit below the PMDA Act in the regulatory hierarchy. Complying with the Guidelines addresses part of the PMDA Act's requirements — not all of them. Post-marketing safety information management, GVP regulations, and other provisions also apply.

So why (why it is written this way): A compliance program built around the Guidelines alone will have blind spots in other PMDA Act domains. Knowing that multiple legislative frameworks overlap is the precondition for designing a compliance system that actually covers all of them.

03Industry Association Self-Regulatory Standards

Companies that belong to industry associations — the Japan Pharmaceutical Manufacturers Association and similar bodies — are bound by those associations' codes of practice and self-regulatory standards. These standards often set a higher bar than statutory law. "We comply with the law but not with the industry code" is a compliance problem, not an acceptable position.

So what (what it means): Self-regulatory standards are not optional for member companies. Membership creates a genuine obligation. Violations damage the company's standing within the industry and can trigger increased regulatory scrutiny from government authorities.

So why (why it is written this way): Industry codes fill the operational detail that legislation cannot reach. If companies treat them as optional, the system of self-regulation loses its effectiveness — and the likely consequence is tighter statutory regulation, which is worse for all participants.

04The Practical Challenge of Satisfying Multiple Frameworks Simultaneously

Meeting the Guidelines, the Fair Competition Code, the PMDA Act, and association self-regulatory standards simultaneously is a genuine operational challenge. Each framework applies its own criteria to the same activity, and each must be checked independently. A review process that looks only at the Guidelines is structurally incomplete — it will produce clean Guidelines assessments alongside undetected violations elsewhere.

So what (what it means): The review process for sales information activities must be designed as a multi-framework checklist, not a single-framework gate. The operational solution is to map each activity against all applicable frameworks at the review stage, before the activity commences.

So why (why it is written this way): Formal compliance with one framework while ignoring others does not constitute genuine compliance — it is selective compliance. The only way to satisfy accountability to patients and society is to keep all applicable rules simultaneously in view throughout the activity planning and review process.